Peroxisome proliferator-activated receptors: are they involved in atherosclerosis progression?

被引:28
|
作者
Puddu, P [1 ]
Puddu, GM [1 ]
Muscari, A [1 ]
机构
[1] Univ Bologna, S Orsola M Malpighi Hosp, Dept Internal Med, I-40138 Bologna, Italy
关键词
atherosclerosis; fibrates; peroxisome proliferator-activated receptors; inflammation; thiazolidinediones;
D O I
10.1016/S0167-5273(02)00565-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Peroxisome proliferator-activated receptors (PPAR) are nuclear receptors present in several organs and cell types. They are subdivided into PPAR alpha, PPAR gamma and PPAR delta (or beta). PPAR alpha and gamma are the two main categories of these receptors, which are both characterized by their ability to influence lipid metabolism, glucose homeostasis, cell proliferation, differentiation and apoptosis, as well as the inflammatory response, by transcriptional activation of target genes. PPAR alpha are activated by fatty acids, eicosanoids and fibrates, while PPAR gamma activators include arachidonic acid metabolites, oxidized low density lipoprotein and thiazolidinediones. Atherosclerosis is now considered a chronic inflammatory condition. Thus, PPAR activation appears a promising approach to favorably affect atherosclerosis development through both metabolic and anti-inflammatory effects. However, the clinical data in favor of an anti-atherosclerotic action of PPAR agonists are still scanty, and some experimental data would even indicate possible pro-atherogenic effects, or a lack of effect in the female sex. New controlled clinical studies will provide the information necessary to understand the true significance and usefulness of PPAR alpha, gamma and delta activators in the control of atherosclerotic disease. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:133 / 140
页数:8
相关论文
共 50 条
  • [1] Peroxisome Proliferator-Activated Receptors and Atherosclerosis
    Soskic, Sanja S.
    Dobutovic, Branislava D.
    Sudar, Emina M.
    Obradovic, Milan M.
    Nikolic, Dragana M.
    Zaric, Bozidarka L.
    Stojanovic, Srdan D.
    Stokic, Edita J.
    Mikhailidis, Dimitri P.
    Isenovic, Esma R.
    [J]. ANGIOLOGY, 2011, 62 (07) : 523 - 534
  • [2] Peroxisome proliferator-activated receptors in human atherosclerosis
    Lestavel, S
    Chinetti, G
    Bocher, V
    Fruchart, JC
    Clavey, V
    Staels, B
    [J]. M S-MEDECINE SCIENCES, 2001, 17 (05): : 637 - 642
  • [3] Peroxisome proliferator-activated receptors in atherosclerosis and inflammation - An update
    Elangbam, CS
    Tyler, RD
    Lightfoot, RM
    [J]. TOXICOLOGIC PATHOLOGY, 2001, 29 (02) : 224 - 231
  • [4] Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis
    Neve, BP
    Fruchart, JC
    Staels, B
    [J]. BIOCHEMICAL PHARMACOLOGY, 2000, 60 (08) : 1245 - 1250
  • [5] Peroxisome Proliferator-Activated Receptors and Progression of Colorectal Cancer
    Wang, Dingzhi
    DuBois, Raymond N.
    [J]. PPAR RESEARCH, 2008, 2008
  • [6] Peroxisome proliferator-activated receptors and liver X receptors in atherosclerosis and immunity
    Barish, GD
    [J]. JOURNAL OF NUTRITION, 2006, 136 (03): : 690 - 694
  • [7] Variable expression of peroxisome proliferator-activated receptors in human atherosclerosis
    Sueyoshi, S
    Yamada, T
    Esumi, M
    Kusumi, Y
    Niihashi, M
    Tsuru, K
    Imai, S
    Nemoto, N
    Sakurai, I
    Mitsumata, M
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2003, 4 (02) : 217 - 217
  • [8] Peroxisome proliferator-activated receptor γ and atherosclerosis
    Marx, N
    [J]. CURRENT HYPERTENSION REPORTS, 2002, 4 (01) : 71 - 77
  • [9] Peroxisome proliferator-activated receptor γ and atherosclerosis
    Nikolaus Marx
    [J]. Current Hypertension Reports, 2002, 4 : 71 - 77
  • [10] Proliferating peroxisome proliferator-activated receptors
    不详
    [J]. DIABETES OBESITY & METABOLISM, 2000, 2 (05): : 332 - 333